Dr Emilio Garcia Quetglas appointed Chief Medical Officer of AlgoTherapeutix

Dr Emilio Garcia Quetglas appointed Chief Medical Officer of…

On October 1st 2019, AlgoTherapeutix appointed Dr Emilio Garcia Quetglas to the position of Chief Medical Officer of AlgoTherapeutix, in charge of the medical and clinical strategy and execution, as well as the scientific representation of AlgoTherapeutix towards external stakeholders. 

Emilo Garcia Quetglas.

Emilio is a Medical Doctor and a PhD specialized in Clinical Pharmacology. His clinical expertise is based on  18 years spent with patients at the University Clinic of Navarra, in departments of Clinical Pharmacology, Infectious Diseases, A&E, Pain and Cardiac Surgery, followed by 9 years in senior medical functions at Grünenthal, a leading pharmaceutical company in the field of pain. Emilio started as Medical Director, Innovation Therapeutics for Southern Europe, then extended his responsibilities to the whole of the EU, and since 2013 he was Sr Med Dir, Translational Science and Intelligence, Global Clinical Development. Among other projects, he played a significant part in the lifecycle management of lidocaine plaster, and tapentadol, and was the architect and builder of the PainSolve website which incorporates considerable expertise from KOL’s around the world.

AlgoTherapeutix is a French biotech start-up, hosted by the Paris Biotech Santé incubator developing ATX01, a treatment for Chemotherapy-Induced Peripheral Neuropathy.

AlgoTherapeutix SAS

49 rue des Nouvelles – 92150 Suresnes

Contact : contact@algotx.com

Communication : Geneviève Cliquet Consultant – T: +33(0) 607 500 567